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Join the Editorial Staffl 
Authors have been seriously distressed by the long 
wait between acceptance of their papers and their pub-
lication. In fact, processing of manuscripts has been 
considerably slowed by the failure of many authors to 
follow the rules of style that are published in each issue. 
These oversights may include any of the following. Ab-
breviations that are not published in the Council of 
Biology Editors Style Manual, 4th Edition, may not be 
used without explanation; all nonstandard abbreviations 
are to be listed as footnotes to the first page of the article. 
References must be in the prescribed format for our 
Journal; a glance at any recent issue is a ready guide-
and inclusive pages are required. Tables and figures 
(unmounted) must be self-contained and self-explana-
tory and contain no extraneous material that is not 
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appraise the figures to allow the essential features to be 
cleady displayed, but in a minimum of space; t his will 
avoid arbitrary cropping and reduction by the editorial 
staff. All electron micrographs must show space baTS. 
Covering letters accompanying revised manuscripts must 
detail the changes made and address specifically th e 
individual comments and criticisms raised by the review-
ers. Finally, the signed copyright form must be r eturned 
immediately since no paper can be sent to th e publisher 
without it. Attention to these details will certainly 
shorten the time between acceptance and publication for 
many manuscripts. 
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REPORTS 
Comparative Study with Two Polar Types of Murine Leprosy: An 
Involvement of Plasminogen Activator and Its Possible Regulating 
Factor in the Granulomatous Tissue Reaction 
SEIICHI IZAKI, M .D., PH.D., YASUMASA IsozAKI, M .D ., MAsAKo SATOH, M .D., TosHIHIKo HIBINO, M.Sc., 
SAIICRI KON, M.D., AND MASAKATSU IZAKI, M .D. 
Departrnenl of Derma.tology, [wale M edical University School of Medicine, M oriolm, / wale, Japan 
Enzymatic activities in a saline-extractable fraction 
from two polar types of murine lepromas were investi-
gated using pyroglutamyl-glycyl-arginine-p-nitroanilide 
and plasminogen-rich, as well as plasminogen-free, fi-
brin plates. An inhibitor activity for urokinase was also 
measured. C57BL/6NJcl (immunologically high re-
sponder strain) mice inoculated with 2 x 10M Mycobacte-
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rium lepraemurium developed a localized lepromatous 
lesion after 4 weeks. The tissue extracts obtained after 
4-6 weeks exhibited inhibition for urokinase (8.8 IU/ mg 
protein), but no enzymatic activity. After 8-11 w eeks, 
when the lepromas showed an ulcerative change, prom-
inent peptide hydrolytic activity (84_8 nmol / mg protein/ 
min) was demonstrated. The fibrin plate assay confirmed 
that plasminogen activator is predominantly involved 
(26.4 IU /mg protein). The proteolytic activation was ap-
parently correlated with discharge of purulent materials 
containing the bacilli and subsequent limitation of le-
proma development- However, similar modulation of the 
fibrinolytic enzyme-inhibitor system was not shown in 
CBAjN mice (immunologically low responders). The tis-
sue extracts showed a low level of urokinase inhibitor 
activity (1-9 IV/mg protein), but no peptidolytic or plas-
minogen activator activity. Consequently, lepromas 
were· developed progressively until 25 weeks after illfec-
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tion and dissemination from the lepromatous lesion took 
place thereafter. 
In comparison with histologic findings, which revealed 
accumulation of lymphocytes and mononuclear cells in 
the peripheral zone oflepromatous lesions in the C57BL/ 
6NJcl, but not in the CBA/N mice, a controlling mecha-
nism of plasminogen activator in tissue is assumed to be 
involved in the development of the granulomatous tissue 
reaction. 
Depending upon the immunoreactivity of the hosts, two polar 
types of murine lepromas are induced by subcutaneous inocu-
lation of Mycobacterium lepraemurium [1,2]. The immunolog-
ically high responder, C57BL strain, produced a localized 
leproma. In the center of the lesions, the macrophages became 
necrotic and the bacilli within the cells showed morphologic 
abnormality. Lymphocytes and monocytes accumulated around 
the macrophages [3]. Infiltration by nonphagocytic cells has 
been taken as evidence of cell-mediated immunity, because 
leproma grown in athymic mice consisted primarily of macro-
phages in which the acid-fast bacilli continued to proliferate 
[4]. The number of macro phages increased progressively and 
resulted in the systemic infection of the host. 
Participation of the clotting system has been demonstrated 
in different types of hypersensitivity reactions such as Masugi 
nephritis [5], tuberculin reaction [6], and chronic granuloma-
tous tissue reaction [7,8]. A recent investigation using immu-
nofluorescence microscopy has revealed that removal of tissue 
fibrin took place in the hepatic granulomatous lesions in the 
thymus-intact mice infected with Schistosoma mansoni [7]. 
Simultaneously, an i'nhibitor for the urinary plasminogen acti-
vator (urokinase) was found in the hepatic tissue extract [9], 
suggesting that fibrinolytic proteinases may be activated during 
the development of granulomatous inflammation. However, 
detection of the fibrinolytic enzymes was not possible, most 
probably because of the presence of excess inhibitor. 
In the present study we used the murine leproma model to 
investigate the relationship between granulomatous inflamma-
tion and the fibrinolytic enzyme system in mice with and 
without cell-mediated immune responses. We measured the 
hydrolytic activity of the enzyme with a peptide substrate and 
fibrin plates. The inhibitory activity for urokinase was a lso 
measured. 
MATERIALS AND METHODS 
Infection of Animals 
Six C3H mice with lepromas induced by inoculation of Mycobacte· 
rium lepraemurium, Hawaiian strain, were donated by Dr. Kohsaka, 
Department of Leprology, Research Institute for Microbial Diseases, 
Osaka University, Osaka, Japan. The mUl'ine lepromas were excised 
and 100 mg tissue was homogenir.ed with a mortal' in sterilized physi-
ologic saline. Bacterial counts were done, and 2 X lOB bacilli in 0.05-0.2 
ml were inoculated into the sternal area of 120 C57BL/6NJcl strain 
mice (Clea Japan, Inc., Tokyo, Japan) which are the immunologically 
high responders. Instead of athymic 01' C3H strain (immunologically 
low responder) , we 'elected to use 40 CBA/N stTain mice (Clea Japan, 
Inc.) because this strain is also known to be a tow responder (K. 
Kohsaka, personal commu nication). They were injected with the sus-
pension of bacilli. At specified weeks after infection, mice were sacri-
ficed and the subcutaneous nodules were removed and weighed. Small 
portions of tissue were processed fol' paraffin sections to be stained with 
hematoxytin and eosin, and by the' Ziehl-Neelsen method. In addition, 
livers and spleens of 3 mice were removed at-20, 30, and 35 weeks after 
infection alld studied histologically. 
Tissue Extract 
Granu lomatous tissues were separated li'om the epidermis, connec-
tive tissue, and underlying dermomuscular layer under a dissecting 
microscope. Complete dissection of the granulomas was confirmed by 
prepal'ing frozen sections from the edge of the tissue samples. The 
tissues were homogenized in 2 ml of 0.05 M Tris-HCI buffer containing 
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0.10 M NaCI, pH 7.5 (Tris-saline) using a glass homogenizer. In each 
extraction, 0.2 g tissue was used; with smaller lepromas, we pooled the 
samples to yield about 0.2 g. The supernatant was separated after 
centrifugation at 43,000 X g for 30 min at 4°C and passed through a 
Millipore filter, HA membrane, 0.45 ,um in pore size (Japan Millipol'e 
Ltd. , Tokyo). Protein concentration was measured for each extractior: 
[10]. 
Enzyme and Inhibitor Assay 
All measw'ements were made in duplicate. 
Chromogenic tl'i'peptide substrate: Pyroglutamyl-glycyl-al'ginine_p_ 
ni troanilide (Kabi Diagnostica, Stockholm, Sweden) was used because 
the substrate has been shown to have high enzyme affinity to urokinase 
and trypsin but little enzyme affinity to plasmin, thrombin, factor X 
plasma kallikl-ein, and glandular kaLlikl-ein [11]. The enzyme activi t; 
was colorimetrically quantitated in the first cuvette containing 0.85 ml 
of 0.05 M Tris-HCI, pH 8.8, and 0.1 ml of the extract. It was set at 37°C 
in a water-jacketed cell holder in a spectrophotometer, Hitachi 200-20 
eq uipped with an automatic recorder, Hitachi 200. After the additior: 
of 0.05 ml of the 4 mM substrate solution, absorbance at 405 nm was 
continuously recorded to monitor liberated p-nitroaniline. The molal' 
concentration of the free p-nitroaniline was calculated by applying the 
molal' extinction coefficient: E = 10,500. To standardize the catalytic 
activity in this assay system, urokinase (Green Cross Co., Ltd. , Osaka) 
was used as a reference. The second cuvette contained 0.85 ml of t he 
buffer, 0.05 ml of 70 IU/m! of urokinase, and 0.05 ml of the substrate. 
This cuvette yielded 0.42 nmol of p-nitroaniline per minute. For the 
urokinase inhibitor activity, the third cuvette conta ined 0.8 ml of the 
buffer, 0.05 ml of urokinase, and 0.1 ml of the extract. It was incubated 
at 37°C in a water bath and the substrate solution (0.05 ml) was added 
after 30 min. A decreased level of the urokinase activity was calculated 
by 
[pNA]urokinase + [pNA]extract - [pNA]urokinase and extract 
where [PNA] is the concentration of p-nitroaniline liberated. 
Fibrin plate: Since the tripeptide substrate does not discriminate 
trypsin-like enzyme activity from plasminogen activator activi ty in the 
tissue extracts, a semiquantitative assay of fibrino lysis, using fibrin and 
plasminogen, was also done [12]. Plasminogen-rich and plasminogen-
free fibrin plates were fU'st prepared. Forty miJiigrams of c10ttable 
protein of either bovine fibrinogen which contains a constant concen-
tration of plasminogen (95% c\ottable, Miles Laboratories, Inc., Elk-
hal'd, Indiana) or plasminogen-free bovine fibrinogen (90% c1ottab le, 
Miles Laboratories, Inc. ) was dissolved in 10 ml of 0.01 M borate buffer 
pH 7.5, with 0.14 M NaC!. The solutions Wel'e mixed with 0.2 ml of 0.01 
M CaCtz, poured into a Petri dish 8.5 cm in diameter, and clotted by 0.5 
ml of 20 NIH units/ml of bovine thrombin (Mochida P harm. Co., 
Tokyo). 
For the enzyme assay, a 20-,u1 drop of a mixture of 1O,u1 of the seriaJiy 
diluted extract and 10 ,ul of Tris-saline were placed on plasminogen-
rich and plasminogen.-free fibrin plates. The area of lysis was measured 
after incubation at 37°C for 18 hr. To standaJ'dize the fibrinolytic 
activity, a 20-1-t1 drop of a mixture of 10,u1 of 0.3, 0.6, 1,2,3, and 4 IU / ml 
of urokinase and 1O,u1 of Tris-saline were placed on the plasminogen-
rich fibrin plates. Similru'ly, various concentrations of human standru'd 
plasmin (Green Cross Co., Ltd.) were used on the plasminogen-free 
fibrin plates. For inhibitor activity, a 20-,u1 drop of 10 ,ul of the serially 
diluted extract and 10,u1 of 3 IU/ml of ul'Okinase were placed on the 
plasminogen-rich fibrin plates. The ar!'la of lysis was measured and 
inhibitor activity was calculated in the same way as described for the 
tripeptide substrate assay. 
RESULTS 
C57BL/6NJcl Strain 
Subcutaneous nod ules that were solitary and firm to the 
touch developed at the site of inoculation by 4-5 weeks after 
infection. After 9-12 weeks of infection, the lesions showed 
cutaneous ulceration with purulent discharge (Fig lA). The size 
of the lesions, measured by weight, increased rapidly dW'ing the 
first 7 weeks and remained at a plateau thereafter (Fig 2). By 
4 weeks after infection, histologic examination revealed infiltra-
tion of mononuclear cells and lymphocytes in the subcutaneous 
layer. After 5, 6, and 7 weeks, the cells infiltrating the center of 
the lesions showed a foamy apperu·ance. Ziehl-Neelsen stain 
identified numerous acid-fast bacilli in the cytoplasm. On t h e 
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FI G 1. Macroscopic observation of murine lepromas. A, C57BL/ 
6NJcI, 6 (left) and 11 (right) weeks after infection. Subcutaneous 
nodules are developed on the stem al area of both mice. Ulceration is 
observed on the older lesion. B, CBA/ N, 20 (left) and 28 (right.) weeks 
after infection. Murine lepromas are seen in nearly theu' maximum size, 
showing a necrotic change of the covering skin on the older lesion. 
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FIG 2. Modulation of the weight of murine lepromas in C57BL/ 
6NJcI and CBA/N mice. Mean values and standard en ol's (bars) are 
illustrated. 
other hand, mononuclear cells, lymphocytes, and fibrobl asti,~ 
cells, which appeared in t he peripheral 3l'ea of the lesions, did 
not contain acid-fast bacilli. By 10, 12, and 15 weeks after 
infection, when ulceration occulTed, t he innermost layer was 
filled with necrotic macrophages a nd nuclear debris. Cells con-
taining the bacilli formed the second inner layer. Lymphocytes 
a nd mononucle31' cells without bacilli formed t he surrounding 
outermost layer (Fig 3A). Fibroblastic cells were found in the 
peripheral zone. In the present investigation, no gia nt cells were 
found dUl'ing the observation period. Livers and spleens did not 
show dissemination of leprotic lesions by 35 weeks after infec-
tion. 
The peptide hydrolytic activity and inhibition for Ul'okinase 
measured in 3 different stages for th e development of mUl'ine 
lepromas-initial (4-6 weeks) , middle (8-11 weeks), a nd late 
(15-34 weeks)-31'e summarized in Fig 4. In the e31'ly period of 
granuloma developmen t, the tissue extract demonstrated an 
inhibitory effect for the Ul'okinase; the extracted protein 1 mg 
inhibited 8.8 ± 1.4 (mean ± S.E.) IU of Ul'okinase activity. 
However , no hydrolytic activi ty was detected in the extract. In 
contrast, when the granulomas with central necrosis developed, 
the tissue extract exhibited extensive catalytic activity which 
hydrolyzed 84.8 ± 14.0 nmol of the substrate/mg protein/ min. 
This activi ty corresponds to 707 ± 104 IU/ mg protein. In the 
older lesions, the t issue extracts showed lower hydrolytic activ-
ity in 4 of 8 mice; the other 4 mice showed inhibitor activity fo), 
Ul'okinase without hydrolytic activity. 
The plasminogen-rich fibrin plate assay confirmed t hat a 
modulation of fibrinolytic enzyme activity occurred in parallel 
during the leproma development (Table I) ; no or only trace 
amounts of fibrinolytic activity was seen on the plasminogen-
free fibrin plates. These findin gs established that the hydrolytic 
activity measUl'ed by the syn thetic substrate represents mainly 
the activity of plasminogen activator. 
FIG 3. Histopathology. Ziehl-Neelsen, original magnification x 100. 
A C57BL/ 6NJcl, 15 weeks. Cells that do not contain acid-fast bacilli 
s~J'J'ound the grouped macrophages phagocytizing the bacilli. T he most 
inner layer (to the left) shows disintegration of the cells. B , CBA/ N, 15 
weeks. Macrophages containing numerous acid-fast bacilli uniformly 
occupy ,the entu'e lesion. 
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TABLE 1. Fibrinolytic activity in C57Bl/ 6NJclm.ice 
Fibrin plate 
P lasminogen-rich 
P lasminogen-free 
4-6 weeks 
o 
o 
Weeks after infection 
8- 11 weeks 
26.4 ± 6.1" 
0.093 ± 0.035" 
15-34 weeks 
4.8 ± 3.4" 
0.043 ± 0.025" 
" International units of urokinase/mg protein (mean ± S.E.) . 
b Casein units of standard human plasrnin/ mg protein (mean ± S.E .) . 
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F I G 5. Peptide hydrolytic enzyme and urokinase inhibi tor in CBA/ 
N mice before and after reaching the maximum size of lepromas. Mean 
values are expressed by the column length. Characteristic morphologic 
changes are illustrated for correlation. 
TABLE II. Fibrinolytic activity in CBA / N mice 
Weeks after infection 
Fibrin plate 
15- 25 weeks 28-35 weeks 
P lasminogen-rich 0" 0 
P lasminogen-free 0 0 
" One out of 5 mice exhibi ted 0,071 IV of uJ'Okinase/ mg protein. 
CBA/N Strain 
Subcutaneous lesions became palpable at 11 weeks after 
infection, exhibi ting a soft tactile and ill-defin ed character. 
After 28 weeks, a large tumor developed, and the skin covering 
the lesion became atrophic a nd necrotic (Fig IB) . The weight 
of the leproma increased progress ively and continued until 25 
weeks a fter infection with a linear curve on the semilogarit hmic 
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graph, reaching a plateau level of approximately 3 g (Fig 2) . 
Histologically, hematoxylin and eosin preparations revealed 
that infiltrating cells with foamy cytoplasm occupied the entire 
lesion. Numerous acid-fast bacilli were contained in the cyto-
plasm of all the m acrophages at 6-35 weeks of infection (Fig 
3B). No lymphocytes were observed in t he lesions. After 25- 35 
weeks of infection, the livers and spleens showed disseminated 
lepromatous lesions containing acid-fast bacilli. 
The peptide hydrolytic and urokinase inhibitor activity meas-
ured at two different stages before and after reaching the 
maximum weight of lepromas are summarized in Fig 5. Before 
reaching the maximum weight, inhibitor activity for urokinase 
(1.95 ± 0.43 IU / mg pro tein) was observed in a ll of the prepa-
ra tions of tissue extract, whereas little or no hydrolytic activi ty 
(0.07 ± 0.05 nmol/mg protein/ min) was observed. In the lesions 
after 28 weeks or more, inhibitor activity for urokinase was 
similarly observed but no hydrolytic activity was induced. 
The fibrin plate assay did not detect fibrinolytic activity on 
either plasminogen-rich or plasminogen-free fibrin plates 
(Table II). However, the tissue extract showed urokinase inhib-
itor activity (1.80 ± 0.40 IU/mg protein). These observations 
confirmed that plasminogen activator is not contained in th e 
t issue extracts of murine lepromas of this strain. 
DISCUSSION 
Lepromatous lesions with two typical histologic characteris-
tics were developed in the C57BL/6NJ cl a nd CBA/ N mice. 
The leproma of the C57BL/6NJcI mice showed accumulation 
of lymphocytes and mononuclear cells wi thout acid-fast bacilli 
in addi t ion to phagocytic cells, while in t he CBA/ N mice the 
lepromas consisted of only phagocytic cells. Closs and Haugen 
[3] correlated the cells without the bacilli with th e immunoge-
netic condition of the mouse strains, a nd characterized them as 
"reactive" cells . The his tologic appearance in both mouse 
strains was associated wit h the difference in th e fibrinolytic and 
a ntifibrinolytic activi ty of the lepromatous t issue. By use of 
synthetic and natural substrates we found that the 
"immunoreactive" lepromas in the C57BL/ 6NJcI mice showed 
3 phases in the disease process. In the early stage of the disease, 
the enzyme activity was not detectable, while enha nced inhib-
itor activity for urokinase was present. The enzym e-inhibitor 
relationship was reversed at the approximate t ime when a 
necrotic cha nge was observed inside the lepromas, and both 
enzymatic a nd inhibitory activities decreased in the older le-
sions. In contrast, the CBA/ N mice showed that the enzyme 
activity was not detectable and inhibitor activity mainta ined 
the low level in the immunologically " noru'eactive" lepromas . 
Since the immunologic reaction in murine leprosy has been 
shown to be mediated by transferable cells but not humoral 
antibody [13], the present resul ts suggest that the enzyme-
inhibitor mechanism is intimately related to t he cell-mediated 
hypersensitivity r eaction against the murine leprosy bacilli. 
The chl'Omogenic tripeptide substrate h as been utilized to 
distinguish between inhibitors for the two steps of fibrinolysis: 
plasminogen activation a nd fibrin degradation [9,14]' The pep-
tide assay revealed the occurrence of the urokinase inhibitor in 
the lepromatous tissue in the present study, as has been dem-
onstrated in hepatic granulomas in murine schistosomiasis [9]. 
We have suggested t hat the induction of proteinase inhibitors 
reflects a latent activation of proteolysis [7,15]. As expected, 
the present study clearly showed an enzymatic activation in the 
C57BL/ 6NJcl mice by use of the sam e substrate. The addi t ional 
fibrin plate assay consistently demonstrated that the enzyme 
de tectable in lepromas of C57BL/6NJcl mice primarily r epre-
sented plasminogen activator. Although contaminat ion with 
unidentified trypsin-like activity is possible, the plasminogen 
activator demonstrated in this study accounts for the prev ious 
observation that deposited fibrin was diminished in thymus-
intact mice during the development of granulomatous infl am-
mation [7]. In the CBA/N mice, nOru'esponder hosts, a mild 
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increase of urokinase inhibitor was detected continuously. This 
may again suggest that a sm all amount of plasminogen activator 
is released in the lepromatous tissue, (but inactivated promptly 
by excess inhibitor). This view is supported by recent experi-
ments with cultured macrophages. Gordon, Unkeless, a nd Cohn 
[16] demonstrated that macrophages secrete plasminogen ac-
tivator after phagocytosis of indigestible particles such as latex 
and bacteria, although the level of plasminogen activator was 
found low. The minimum enzymatic co ndition is consistent 
with the previous finding in athymic mice with experimental 
schistosomiasis [7]. The granulomas of athymic mice showed 
neither the increase of fibrinolysis inhibitor nor the fibrin 
clearing. 
Two types of enzyme-inhibitor responses to invasion with 
acid-fast bacilli are associated with different tissue reactions. In 
the C57BL/6NJcl mice, the necrotic cha nge and localization of 
lepromatous tissue are correlated with the enzymatic change. 
In the CBA/N mice no necrosis was observed inside the lepro-
mas; the static proteolytic condition seems to allow the pro-
gressive proliferation of the acid-fast bacilli in the cytoplasm of 
phagocytic leprosy cells. Although in the present study we did 
not determine cell types responsible for the enzyme and inhib-
itor, the prominent activity of plasminogen activator in t he 
C57BL/6NJcl mice was correlated with the presence of a mono-
nuclear cell reaction in the peripheral ar ea of the lepromas. The 
histologic findings suggest that ly mphocytes and monocytes 
playa role in the enzymatic activation . An immunologic induc-
tion of plasminogen activator by cultured cells has been re-
ported in T,ypanosoma cruzi [17] and Bacille Galmette-GUlirin 
(BGG) [18] infection . The sensitizied T lymphocytes were 
shown to activate "resident" peritoneal macrophages, inducing 
a secretion of plasminogen activator. Furthermore, it was shown 
possible that a level of plasminogen activator significantly in-
creases by combination of two different stimuli [16] of latex 
phagocytosis and of BGG, endotoxin, fetal calf serum, or mineral 
oil. In C57BL/6NJcl mice both T-cell activation and phagocy-
tosis of the bacilli may participate in the extensive discharge of 
plasminogen activator that was able to exceed the inhibitor 
level. Additionally, r e leased plasminogen activator may fully 
act in the presence of denatured a nd necrotic protein and fibrin, 
as shown in vitro by Radcliffe and Heinze [19]. Other cells that 
secrete fibrinolytic enzymes such as neutrophils [20,21], vascu-
lar endothelium [22,23], and fibroblasts [24,25] do not success-
fully correlate the plasminogen activator activity with the 
mononuclear cell reaction in the mycobacterial infection. 
Clinical observations have been reported that human leprosy 
involved analogous enzyme-inhibitor systems. Tissue extracts 
and plasma of patients with lepromatous leprosy exhibited an 
inhibitory activity for fibrinolysis [26,27]. However, during the 
treatment of patients with sulfonamides, fibrinolytic activity in 
tW"n dominated. In addition, t-aminocyclohexanoic acid, an 
agent of fibrinolysis inhibitor [28], has been shown to be effec-
tive for the treatment of erythema nodosum leprosum. The 
biochemical characterization of plasminogen activator and uro-
kinase inhibitor in murine leprosy is in progress in order to 
elucidate the role of the enzym e-inhibitor relationship in gran-
ulomatous inflammation. 
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